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Abstract
Background: In recent years, the completion of the Human Genome Project and other rapid
advances in genomics have led to increasing anticipation of an era of genomic and personalized
medicine, in which an individual's health is optimized through the use of all available patient data,
including data on the individual's genome and its downstream products. Genomic and personalized
medicine could transform healthcare systems and catalyze significant reductions in morbidity,
mortality, and overall healthcare costs.
Discussion: Critical to the achievement of more efficient and effective healthcare enabled by
genomics is the establishment of a robust, nationwide clinical decision support infrastructure that
assists clinicians in their use of genomic assays to guide disease prevention, diagnosis, and therapy.
Requisite components of this infrastructure include the standardized representation of genomic
and non-genomic patient data across health information systems; centrally managed repositories of
computer-processable medical knowledge; and standardized approaches for applying these
knowledge resources against patient data to generate and deliver patient-specific care
recommendations. Here, we provide recommendations for establishing a national decision support
infrastructure for genomic and personalized medicine that fulfills these needs, leverages existing
resources, and is aligned with the Roadmap for National Action on C l i n i c a l  D e c i s i o n  S u p p o r t
commissioned by the U.S. Office of the National Coordinator for Health Information Technology.
Critical to the establishment of this infrastructure will be strong leadership and substantial funding
from the federal government.
Summary: A national clinical decision support infrastructure will be required for reaping the full
benefits of genomic and personalized medicine. Essential components of this infrastructure include
standards for data representation; centrally managed knowledge repositories; and standardized
approaches for leveraging these knowledge repositories to generate patient-specific care
recommendations at the point of care.
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Background
The Promise of Genomic and Personalized Medicine
Through the 1990s and into the current millennium,
rapid advances in genomics and related disciplines have
made it possible to envision a healthcare system in which
patient care is routinely optimized through the use of
information on individuals' genomes and their down-
stream products (i.e., transcriptomes, proteomes, and
metabolomes). Genomic medicine, or the use of genomic
information to optimize health and healthcare [1], is a
critical component of personalized medicine, which
entails the optimization of individuals' health through a
consideration of all available patient data, including
molecular data on patients' genomes, transcriptomes,
proteomes, and metabolomes [1,2]. Because variations in
individuals' genetic profiles oftentimes correlate with dif-
ferences in how individuals develop diseases and respond
to treatment, personalized medicine supported by genetic
and genomic assays has the potential to facilitate optimal
risk identification, disease screening, disease diagnosis,
therapy, and monitoring [1,2].
In addition to genomic assays, proteomic and metabo-
lomic signatures hold great potential for serving as pillars
of personalized medicine in the future [3-7]. At present,
however, genomic assays (including gene expression pro-
filing and genome sequence analysis) appear better
poised than proteomic and metabolomic signatures for
overcoming the technical, scientific, and logistical barriers
to achieving widespread clinical use in the near future [4-
6,8]. Thus, our discussion of personalized medicine in
this manuscript focuses primarily on the clinical use of
genetic and genomic assays.
While personalized medicine guided by genomics is still
in early stages of development, individuals' genetic pro-
files are already starting to be used to guide patient care.
As some examples, clinicians can obtain gene expression
profiles of breast cancer samples to guide management
[9], genotypes of HIV samples to identify the optimal
antiretroviral regimen [10], and genetic profiles of
patients' cytochrome P450 drug metabolizing system to
guide the selection and dosing of pharmacotherapies [11].
In the coming years, we expect that many more validated
genetic and genomic assays will become clinically availa-
ble for guiding patient management. In particular, given
the significant role of genetic variability in determining
how patients respond to pharmacotherapy [12], validated
genetic and genomic tests may soon be available for guid-
ing the pharmacotherapy of a variety of common diseases
including asthma [13], hyperlipidemia [14], hypertension
[15], and various cancers [16]. By enabling individually
tailored medical interventions associated with improved
effectiveness, reduced side effects, and greater patient
compliance, genetic and genomic assays could transform
healthcare systems and lead to significant reductions in
morbidity, mortality, and overall healthcare costs [1,2].
Challenges to Genomic and Personalized Medicine
Despite the great promise of the clinical use of genomics,
many obstacles lie in the way of integrating genomic and
personalized medicine into routine clinical care. These
challenges include the need for greater oversight and qual-
ity assurance of genetic testing [17]; limited availability of
rigorous, prospectively collected evidence on the clinical
value and cost effectiveness of genetic and genomic assays
[17-22]; concern among pharmaceutical companies that
the tailoring of pharmaceuticals to genetic sub-popula-
tions may segment the marketplace and reduce the
number of patients for whom a given medication is indi-
cated and prescribed [21]; and the limited knowledge of,
and comfort with, genetics and genomics among health-
care professionals [17,19,22,23].
In this manuscript, we focus on the need for a robust
health information technology (IT) infrastructure sup-
portive of appropriate clinical decision making based on
the results of genetic and genomic assays combined with
other clinical data. Of note, this need has been identified
as a critical requirement for realizing the promise of per-
sonalized medicine by the U.S. Secretary of Health and
Human Services [24] as well as by others [21,25]. How-
ever, it is important to keep in mind that the need for a
decision support infrastructure represents just one of sev-
eral substantial obstacles that must be overcome before
genomic and personalized medicine can become routine
components of clinical care.
Need for Clinical Decision Support
Despite the potential for genomics to transform health-
care, past experience indicates that new genomic interven-
tions, like any new medical intervention, will remain
substantially underutilized for many years unless a robust
infrastructure is established for supporting their appropri-
ate use. Clinical research results require an average of 17
years to be routinely implemented in clinical practice
[26], and a landmark 2003 study assessing 439 quality
indicators found that U.S. adults only receive about half
of recommended care [27]. Moreover, genomic interven-
tions may face even greater barriers to clinical adoption
compared to more traditional medical interventions, due
to such factors as limited clinician familiarity with genom-
ics [23] and the volume and complexity of the underlying
data that may need to be considered.
Of the many strategies that have been evaluated for pro-
moting evidence-based care, one strategy has been found
to be particularly effective: clinical decision support
(CDS), which entails providing clinicians, patients, and
other healthcare stakeholders with pertinent knowledgeBMC Medical Informatics and Decision Making 2009, 9:17 http://www.biomedcentral.com/1472-6947/9/17
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and/or person-specific information, intelligently filtered
or presented at appropriate times, to enhance health and
healthcare [28]. Over 90% of clinician-directed CDS inter-
ventions evaluated in randomized controlled trials have
significantly improved patient care, provided that the
CDS was delivered automatically as a part of clinician
workflow, offered at the time and location of decision
making, recommended a specific course of action, and
used a computer to generate the recommendation [29].
Extended to genomic and personalized medicine, CDS
could support the consistent and evidence-based applica-
tion of genetic and genomic information in healthcare in
many ways. For example, when initiating warfarin therapy
using an electronic prescribing system, a clinician could
be provided with recommendations on dosing and mon-
itoring that account for the patient's CYP2C9 and
VKORC1 genotype [30]. As another example, to support a
clinician in his treatment of a patient with breast cancer,
an electronic health record (EHR) system could consider
the gene expression profile of the patient's cancer biopsy
and provide an individually-tailored prediction of how
the patient is likely to respond to various therapeutic
options [9]. In championing this vision, Secretary Leavitt
of the U.S. Department of Health and Human Services has
identified the enabling of personalized healthcare
through health IT a priority area of the department [24].
Moreover, the Secretary's Advisory Committee on Genet-
ics, Health, and Society has identified CDS as an impor-
tant component of the health IT infrastructure required
for the widespread and effective practice of personalized
medicine [25].
Critical to this vision of genomic and personalized medi-
cine supported by IT will be a national CDS infrastructure
that enables authoritative, centrally-curated knowledge
on genomic medicine to be consistently leveraged in clin-
ical practices across the nation. In this manuscript, we
define the essential components of this infrastructure,
explain why each component is needed, and provide rec-
ommendations for establishing this infrastructure. While
we focus primarily on the needs facing the U.S. healthcare
system, we anticipate that our recommendations will be
helpful to the healthcare stakeholders of any nation seek-
ing to reap the full benefits of genomic and personalized
medicine.
Discussion
Required Infrastructure Components
In order to provide CDS, several prerequisites must be
met. First, there must be medical knowledge available on
how patients should be managed, and that knowledge
must be encoded in a format that can be processed by a
computer to generate patient-specific advice in an auto-
mated manner. Second, the patient data required for gen-
erating these inferences must be available in a format that
can be interpreted by a computer. Finally, a mechanism
must be in place for applying the computer-processable
medical knowledge against the patient data to generate
patient-specific assessments and recommendations. This
advice can then be communicated to clinicians, patients,
and other healthcare stakeholders to guide their decision
making.
A national CDS infrastructure is required for genomic and
personalized medicine because the CDS prerequisites just
described cannot be efficiently fulfilled unless certain
infrastructure components are in place. These required
infrastructure components are outlined in Table 1. Of
note, these infrastructure needs exist not only for genomic
and personalized medicine but for all aspects of tradi-
tional clinical care as well. Due in large part to the lack of
Table 1: Infrastructure components required for meeting CDS prerequisites
CDS Prerequisite Needed Infrastructure Component Reason for Need
Computer-processable medical knowledge Centrally managed repositories of computer-
processable medical knowledge
Most healthcare organizations lack the 
resources to create and maintain required 
knowledge repositories for themselves
Standardization of CDS information provided 
for specific aspects of genomic medicine
All knowledge resources should provide 
consistent CDS information for common 
aspects of genomic medicine
Computer-interpretable patient data Standardized representation of patient data Variable representation of patient data makes 
CDS resources difficult to re-use across 
different settings
Generation of patient-specific advice using 
knowledge and patient data
Standard approaches for leveraging computer-
processable medical knowledge
Disparate approaches to integrating knowledge 
resources make such resources difficult to re-
use across different settings
Standard approach for locating and retrieving 
patient data
Patients receive care across institutional 
boundariesBMC Medical Informatics and Decision Making 2009, 9:17 http://www.biomedcentral.com/1472-6947/9/17
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these infrastructure components, only limited CDS capa-
bilities are currently available for supporting traditional
medical care in the vast majority of healthcare settings, if
at all [28]. This need for a national CDS infrastructure will
only be exacerbated as the number of genomics-based
clinical management algorithms increases rapidly, and
perhaps exponentially, in the coming years.
One critical component of a national CDS infrastructure
is centrally managed repositories of authoritative, compu-
ter-processable knowledge on how genetic and genomic
interventions should be utilized clinically. Knowledge
resources included in these repositories may consist of
two broad types of resources: knowledge resources that
encapsulate only the core medical knowledge underlying
a clinical decision (e.g., knowledge on how to calculate
the optimal warfarin initiation dose given a patient's phe-
notype and genotype [30]), and knowledge resources that
encapsulate both the core medical knowledge as well as
additional business logic on how the resource should be
utilized in a specific setting (e.g., when a warfarin order is
placed with a computerized provider order entry system,
relevant clinical and genetic parameters should be col-
lected from the EHR and from the ordering clinician; the
optimal warfarin dose should then be calculated; and the
calculated dose should be presented to the clinician as the
default ordering dose along with an explanation) [31]. For
the purposes of this manuscript, the former type of knowl-
edge resource will be referred to as context-independent
knowledge resources, and the latter type will be referred to
as context-inclusive knowledge resources. A context-inclu-
sive knowledge resource is easier to utilize when the
resource is being used in the context in which it was
intended (e.g., the order entry system of a specific ven-
dor), whereas a context-independent knowledge resource
is easier to utilize when the resource is being leveraged in
a different setting. Of note, a context-independent knowl-
edge resource may be leveraged to generate one or more
context-inclusive knowledge resources tailored to specific
use contexts.
Because the task of creating and maintaining computer-
processable medical knowledge requires significant exper-
tise and effort, most healthcare organizations lack the
resources to create and maintain these knowledge reposi-
tories for themselves. Thus, centrally managed repositor-
ies of computer-processable knowledge are needed to
enable CDS for genomic and personalized medicine on a
widespread basis. Organizations that could lead this
knowledge management process include academic medi-
cal centers, professional associations, governmental agen-
cies, and commercial entities. With regard to the potential
role for corporations, companies such as First DataBank
[32], Thomson Reuters® [33], Elsevier® [34], Wolters Klu-
wer® Health [35], and Zynx® Health [36] may offer struc-
tured, computer-processable medical knowledge for
personalized medicine in a manner similar to how they
currently offer drug-drug interaction knowledge and struc-
tured order sets. Many of these companies, as well as oth-
ers such as WebMD®  [37], also provide narrative
educational content that could be expanded to help clini-
cians and patients better understand the appropriate use
of genetic and genomic assays.
A second CDS infrastructure requirement is the standard-
ization of the CDS information to be provided for various
aspects of genomic and personalized medicine. For exam-
ple, for the interpretation of gene expression analyses of
cancer specimens, agreement could potentially be reached
that CDS for this type of assay should include the recom-
mended course of therapy, the expected survival of the
patient on different therapies, and the evidence base
underlying the assessment. Such standardization of CDS
content across knowledge repositories will enable clini-
cians to more easily interpret and act on care recommen-
dations regardless of the knowledge repository utilized for
generating the CDS.
A third vital component of a national CDS infrastructure
for genomic medicine will be the standardization of how
relevant genomic and non-genomic patient data are repre-
sented in health information systems. Currently, there is
significant heterogeneity in the way in which different
clinical practices and health information systems capture
and record electronic patient data, including genomic
data [28]. Such heterogeneity is a significant problem
because this variability can make it very difficult to take a
CDS resource developed for one clinical setting and to re-
leverage that resource in other settings [28]. To enable the
efficient deployment of CDS capabilities, both the infor-
mation models used to represent patient data and the ter-
minologies used to identify concepts within those models
will need to be standardized. Moreover, to enable truly
personalized healthcare, existing clinical terminologies
such as the Systematized Nomenclature of Medicine –
Clinical Terms (SNOMED CT®) [38] and the Logical
Observation Identifiers Names and Codes (LOINC®) [39]
will need to be extended to encompass relevant concepts,
such as genomically defined disease subtypes and
genomic assay results. Moreover, if existing terminologies
cannot be appropriately extended, new terminologies
may need to be developed.
A fourth critical component of a national CDS infrastruc-
ture will be standard approaches for independent compu-
ter systems to leverage computer-processable genomic
knowledge repositories and patient data to guide clinical
decision making. Such approaches will need to include
standard methods for identifying and accessing relevant
knowledge resources, so that knowledge resources can beBMC Medical Informatics and Decision Making 2009, 9:17 http://www.biomedcentral.com/1472-6947/9/17
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efficiently utilized by various clinical information sys-
tems. One cross-industry technology platform that could
be leveraged for such knowledge sharing is Web services
technology, which entails the provision of software capa-
bilities through the standardized communication of
extensible markup language (XML) messages over the
Internet [40]. For example, knowledge repositories could
provide a standard Web service interface for clients to
search for knowledge resources of interest. Then, these
repositories could provide a standard Web service inter-
face for retrieving these resources in a standardized format
(e.g., genetic risk assessment algorithms implemented in
a standard rule expression format such as GELLO [41] or
the Arden Syntax [42]). Alternatively, these repositories
could provide a standard Web service interface for directly
obtaining patient-specific inferences utilizing these
resources. For example, a warfarin dosing module within
a knowledge repository could accept relevant clinical and
genetic parameters as Web service inputs and return the
recommended dosing and rationale as the output.
Finally, a fifth critical component for a national CDS
infrastructure will be a standard approach for locating and
retrieving patient data from across disparate health infor-
mation systems. Such standardized data retrieval is critical
to ensure that all patient data relevant for a clinical deci-
sion can be efficiently and securely collected from the var-
ious healthcare organizations participating in the care of a
given patient. Fortunately, the U.S. Health Insurance Port-
ability and Accountability Act (HIPAA) permits such
health information exchange among organizations that
have entered into HIPAA business associate agreements,
provided that appropriate privacy and security safeguards
have been put into place [43].
Relevant Resources
In designing, developing, and implementing a national
CDS infrastructure for genomic and personalized medi-
cine, it will be important to leverage available resources.
Table 2 outlines several notable resources that could be
leveraged for establishing the required CDS infrastructure
components.
First, with regard to the creation of centrally managed
repositories of computer-processable medical knowledge,
methods for generating authoritative knowledge on the
appropriate use of genetics and genomics in clinical med-
icine have been developed by groups including the U.S.
Preventive Services Task Force [44], which is sponsored by
the U.S. Agency for Healthcare Research and Quality
(AHRQ), and by the Evaluation of Genomic Applications
in Practice and Prevention initiative [45], which is spon-
sored by the U.S. Centers for Disease Control and Preven-
tion (CDC). These efforts and their associated
methodologies could be applied systematically to emerg-
ing genetic and genomic interventions to provide defini-
tive guidance on how they should be used in practice.
Moreover, the creation of such guidance can be facilitated
by the availability of centrally managed repositories of
structured experimental data relevant to genomic medi-
cine. For example, the Pharmacogenetics and Pharmacog-
enomics Knowledge Base (PharmGKB) offers both
primary data and curated knowledge derived from phar-
macogenetic and pharmacogenomic research studies [46];
the National Center for Biotechnology Information
(NCBI)'s database of Genotype and Phenotype (dbGaP)
provides access to data from studies evaluating the inter-
action between genotypes and phenotypes, including
results of genome-wide association studies [47]; and
NCBI's Gene Expression Omnibus (GEO) offers data from
microarray experiments and other high-throughput
genomic experiments [48].
Once the underlying medical knowledge on the appropri-
ate use of genetic and genomic interventions is available,
various formalisms are available for representing that
knowledge in an appropriate computer-processable for-
mat [49,50]. These approaches include the Arden Syntax
for Medical Logic Modules, which is a formalism for rep-
resenting context-inclusive medical knowledge that is
supported by several commercial EHR systems [42]. The
Arden Syntax has been adopted as a standard by Health
Level 7 (HL7), which is the leading standards develop-
ment organization in healthcare IT internationally [51].
Another relevant HL7 standard is GELLO, which is an
expression language based on the Object Constraint Lan-
guage that can be used to represent data requirements and
decision logic for computer-processable medical knowl-
edge in a platform-independent manner [41]. Other avail-
able formalisms include the Guideline Interchange
Format (GLIF) [52], PROforma [53], and the Standards-
Based Active Guideline Environment (SAGE) [54], which
are context-inclusive formalisms for modeling clinical
practice guidelines in a machine-processable manner.
Also, the System for Evidence Based Advice through
Simultaneous Transaction with an Intelligent Agent across
a Network (SEBASTIAN) [55] provides a mechanism for
accessing context-independent modules of machine-proc-
essable medical knowledge through a Web service inter-
face.
In developing centralized CDS knowledge repositories for
personalized medicine, additional resources that can be
leveraged include the published descriptions of how Inter-
mountain Healthcare in Utah [56] and Partners Health-
Care in Boston [57] have developed enterprise-wide
infrastructures for specifying, developing, and maintain-
ing CDS assets. These knowledge management infrastruc-
tures are used operationally to support the collaborative
specification, authoring, and maintenance of CDS assetsBMC Medical Informatics and Decision Making 2009, 9:17 http://www.biomedcentral.com/1472-6947/9/17
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Table 2: CDS infrastructure needs and available resources
Infrastructure Need Available Resources
Centrally managed repositories of computer-processable medical 
knowledge
Initiatives that can serve as models for creating authoritative knowledge 
on how genomic interventions should be used in clinical practice (e.g., 
U.S. Preventive Services Task Force [44], U.S. Evaluation of Genomic 
Applications in Practice and Prevention initiative [45])
Centrally managed repositories of structured experimental data relevant 
to genomic medicine (e.g., PharmGKB for pharmacogenetic and 
pharmacogenomic experimental data and curated knowledge [46]; NCBI 
dbGaP for data from studies evaluating the interaction between 
genotypes and phenotypes [47]; and NCBI GEO for high-throughput, 
experimental genomic data [48])
Various formalisms for representing medical knowledge in a computer-
processable format [49,50] (e.g., Arden Syntax [42], GELLO [41], GLIF 
[52], PROforma [53], SAGE [54], SEBASTIAN [55])
Large-scale efforts at managing computer-processable medical 
knowledge (Intermountain Healthcare [56], Partners HealthCare [57])
Standardization of CDS information provided for specific aspects of 
genomic medicine
Standard mechanisms for defining CDS information to be provided in 
specified contexts (e.g., HL7 refined message information models [49], 
openEHR Archetypes [58], HL7 Decision Support Service semantic 
profiles [59])
Standardized representation of patient data Standardized information models and terminologies for both genomic 
and traditional patient data [49,60] (e.g., HL7 data standards, including 
HL7 Clinical Genomics data standards [60] and emerging HL7 virtual 
medical record standard [62]; openEHR Archetypes [58]; SNOMED CT 
[38]; LOINC [39]; BSML [60]; MAGE-ML [63]; National Cancer 
Institute/caBIG Common Data Elements [61])
Resources that enable mapping between different terminologies (e.g., 
Unified Medical Language System [65], National Cancer Institute 
Enterprise Vocabulary Services [66], HL7 Common Terminology 
Services standard [67])
Standard approaches for leveraging computer-processable medical 
knowledge
Various approaches for using computer-processable medical knowledge 
resources to provide automated CDS [31] (e.g., Arden Syntax [42], 
SAGE [54], PRODIGY [68], GLIF [69], SEBASTIAN [55], First DataBank 
Drug Information Framework [70], HL7 Decision Support Service [59])
Standard approach for locating and retrieving patient data Standardized approaches for resolving patient identities across systems 
(e.g., HL7 Entity Identification Service draft standard [72] and 
corresponding OMG technical specification [73]) and for locating and 
retrieving patient data across systems (e.g., HL7 Retrieve, Locate, and 
Update Service draft standard [74] and corresponding OMG technical 
specification [75])
Regional and national initiatives for secure health data exchange (e.g., 
U.K. National Health Service Connecting for Health [76], U.S. 
Nationwide Health Information Network prototypes [77], caBIG [78], 
Indiana Health Information Exchange [79])
All infrastructure components Initiatives to share machine-processable medical knowledge (e.g., 
Morningside Initiative [80], U.S. federal CDS Collabatory [81])
Efforts at specifying functional requirements of EHR systems (e.g., HL7 
EHR System Functional Model standard [82], CCHIT EHR certification 
criteria [83])
Efforts at coordinating the use of available health information technology 
standards (e.g., U.S. Health Information Technology Standards Panel 
[84], Integrating the Healthcare Enterprise [85])
BSML = Bioinformatic Sequence Markup Language; caBIG = cancer Biomedical Informatics Grid; CCHIT = Certification Commission for Healthcare 
Information Technology; dbGaP = database of Genotype and Phenotype; EHR = electronic health record; GEO = Gene Expression Omnibus; GLIF 
= Guideline Interchange Format; HL7 = Health Level 7; LOINC = Logical Observation Identifiers Names and Codes; MAGE-ML = microarray and 
gene expression markup language; NCBI = National Center for Biotechnology Information; OMG = Object Management Group; PharmGKB = 
Pharmacogenetics and Pharmacogenomics Knowledge Base; PRODIGY = Prescribing RatiOnally with Decision-support In General-practice studY; 
SAGE = Standards-Based Active Guideline Environment; SEBASTIAN = System for Evidence Based Advice through Simultaneous Transaction with 
an Intelligent Agent across a Network; SNOMED CT = Systematized Nomenclature of Medicine, Clinical TermsBMC Medical Informatics and Decision Making 2009, 9:17 http://www.biomedcentral.com/1472-6947/9/17
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that include narrative clinical guidelines, structured order
sets, and machine-processable clinical decision rules
[56,57]. These efforts are particularly useful in offering
insights into how the efforts of large numbers of users,
and in particular clinician domain experts with limited
technical background, can be harnessed to inform the
specification and implementation of computer-processa-
ble knowledge resources.
Second, with regard to the need for standards on the infor-
mation included in CDS for specific aspects of genomic
medicine, such information content can be standardized
within HL7 as refined message information models,
which are context-specific information models that derive
from a unifying information model known as the HL7
Reference Information Model [49]. Such information
content can also be represented as an openEHR Archetype
[58]. Once defined, such information models could be
designated as the output of a CDS knowledge resource
such as a knowledge module in an HL7 Decision Support
Service. Adopted as an HL7 draft standard in 2006, the
Decision Support Service specification provides a stand-
ard interface for submitting patient data as the input and
obtaining patient-specific inferences using one or more
modules of computable medical knowledge [59].
Third, with respect to the need for standardized represen-
tation of patient data, standard information models and
terminologies are available for representing both genomic
and non-genomic patient data [49,60]. These available
standards include HL7 data standards for traditional med-
ical data such as problem lists, medication lists, and clin-
ical encounter history [49]; HL7 data standards for family
history information and genetic testing data developed by
the HL7 Clinical Genomics Special Interest Group [60];
and data standards developed by the National Cancer
Institute as a part of its cancer Biomedical Informatics
Grid (caBIG®) initiative [61]. Also, there is an effort within
the HL7 Clinical Decision Support Technical Committee
to standardize a "virtual medical record" that defines the
superset of patient data relevant for CDS [62].
The HL7 data standard for genetic testing incorporates
clinically relevant subsets of bioinformatics data stand-
ards, including the bioinformatic sequence markup lan-
guage (BSML) for sequence data [60] and the microarray
and gene expression markup language (MAGE-ML) for
gene expression data [63]. Of note, MAGE-ML complies
with Minimum Information About a Microarray Experi-
ment (MIAME) guidelines [64], which specify the mini-
mal set of data on gene expression assays that should be
included within an assay report to allow for proper inter-
pretation. As for notable terminology resources,
SNOMED CT is a clinical healthcare terminology with
over 311,000 active, hierarchically organized clinical con-
cepts [38], and LOINC is a major terminology of over
50,000 laboratory concepts that includes an expanding set
of codes to identify genetic tests [39].
As additional resources for standardized patient data rep-
resentation, resources are available to map concepts
between terminologies in the case that data are stored
using a terminology different than that used by a knowl-
edge resource. Most notable among these resources is the
National Library of Medicine (NLM)'s Unified Medical
Language System (UMLS), which provides concept map-
pings across over a hundred terminologies [65]. Also, the
National Cancer Institute Enterprise Vocabulary Services
resource, which is based on the UMLS, provides addi-
tional support for several cancer-centric terminologies
[66]. Moreover, the HL7 Common Terminology Services
standard defines a standard interface for accessing such
terminology services [67].
Fourth, with regard to the need for standard approaches
for leveraging computer-processable medical knowledge,
various methods have been developed for providing CDS
using computer-processable medical knowledge resources
[31]. In many of these methods, context-inclusive knowl-
edge resources are loaded into a knowledge resource exe-
cution engine, which in turn interfaces with an EHR
system or other point-of-care clinical information system.
In this approach, the execution engine is triggered when
an activation condition specified in the knowledge
resource occurs. Then, the execution engine retrieves the
required input data from the clinical information system,
generates patient-specific assessments and recommenda-
tions, and communicate these inferences back to the user
through the clinical information system [31]. This
approach to leveraging machine-processable medical
knowledge has been used by CDS approaches that include
the Arden Syntax [42], SAGE [54], PRODIGY [68], and
GLIF [69].
Methods have also been developed for providing CDS
using context-independent knowledge resources. In these
methods, the CDS execution engine typically provides an
interface for submitting patient data as the input and
obtaining patient-specific, computer-processable infer-
ences as the output. In contrast to approaches for utilizing
context-inclusive knowledge resources, this approach
leaves contextual issues related to integrating the knowl-
edge into the clinical information system up to the invok-
ing information system (e.g., considerations of when to
invoke the resource; how to retrieve the required patient
data; and how to communicate the CDS results to the end-
user) [31]. Methods that utilize this approach include
SEBASTIAN [55], the First DataBank Drug Information
Framework [70], and the HL7 Decision Support Service
standard [59].BMC Medical Informatics and Decision Making 2009, 9:17 http://www.biomedcentral.com/1472-6947/9/17
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Fifth, with respect to the need for a standard approach for
locating and retrieving relevant patient data across sys-
tems, relevant standards have been developed though the
Healthcare Services Specification Project (HSSP), which is
a joint initiative between HL7 and the Object Manage-
ment Group (OMG) to develop interoperable service
interface specifications for healthcare [71]. The HSSP has
produced an HL7 draft standard and a corresponding
OMG technical specification for an Entity Identification
Service that resolves the identities of entities (e.g.,
patients) across systems [72,73]. Also, the HSSP has devel-
oped HL7 and OMG standards for a Retrieve, Locate, and
Update Service that enables locating and retrieving patient
data across systems [74,75]. The HL7 Decision Support
Service [59] and HL7 Common Terminology Services [67]
standards described earlier are also a part of this family of
service interface standards. Moreover, potential
approaches for secure, cross-organizational health data
exchange have been explored by a number of efforts,
including the U.K. National Health Service Connecting
for Health [76] initiative, the U.S. Nationwide Health
Information Network (NHIN) prototypes [77], caBIG
[78], and the Indiana Health Information Exchange [79].
Some of the lessons learned from these prior efforts are
discussed in the next section.
Furthermore, in designing and developing all of the infra-
structure components, there is potential for synergy with
two recently initiated, large-scale efforts at sharing CDS
resources across institutions. One of these efforts, known
as the Morningside Initiative, is a collaborative effort
started in November 2007 to develop an open, Web-based
repository of computer-processable medical knowledge
[80]. The collaborators in this initiative are the American
Medical Informatics Association (AMIA), Arizona State
University, the Henry Ford Health System, the Veterans
Health Administration, the Department of Defense, Kai-
ser Permanente, Partners HealthCare System, the U.S.
Telemedicine and Advanced Technology Research Center,
and Intermountain Healthcare. An important goal of this
initiative is to develop a business model and funding
streams for creating such a knowledge repository. A sec-
ond large-scale effort at sharing CDS resources is the U.S.
federal CDS Collaboratory, which is co-sponsored by the
U.S. Office of the National Coordinator for Health Infor-
mation Technology (ONCHIT), AHRQ, and the U.S.
Department of Health and Human Services' Personalized
Health Care Initiative [81]. The first meeting of the Col-
laboratory was held in March 2008, with representatives
from nine U.S. federal agencies participating. The goal of
the Collaboratory is to coordinate CDS efforts across the
U.S. federal government in order to expedite the develop-
ment and widespread adoption of effective CDS capabili-
ties. This Collaboratory therefore provides an existing
platform for coordinating government-sponsored CDS
initiatives within the U.S.
Another type of resource that could be leveraged in estab-
lishing a national CDS infrastructure is efforts at specify-
ing functional requirements of EHR systems, as CDS
capabilities for personalized medicine could be incorpo-
rated within these requirement frameworks. A relevant
resource in this regard is the HL7 EHR system functional
model standard, which defines functional capabilities of
EHR systems and conformance criteria for evaluating the
availability of these capabilities within a given EHR sys-
tem [82]. Furthermore, the Certification Commission for
Healthcare Information Technology (CCHIT) is a non-
profit, private-sector organization which defines func-
tional requirements for EHR systems and provides
certification to those systems that fulfill all of these
defined requirements [83]. Despite only being in exist-
ence since 2004, CCHIT already commands significant
market influence, due to purchasers using CCHIT certifi-
cation as an important criterion in system selection.
Finally, an important challenge to establishing a stand-
ards-based, semantically interoperable infrastructure for
CDS is the fact that overlapping and oftentimes conflict-
ing standards exist for the same purpose [49]. Thus, coor-
dinating the selection and use of standards will be critical
for establishing a CDS infrastructure for personalized
medicine. A prominent effort that could be leveraged for
this purpose is sponsored by the U.S. Health Information
Technology Standards Panel (HITSP). HITSP is a public-
private partnership founded in 2005 to promote interop-
erability by harmonizing and integrating health IT stand-
ards [84], and its current scope of work includes the
coordination of existing standards to support personal-
ized healthcare. Furthermore, Integrating the Healthcare
Enterprise (IHE) is an initiative that was started in 1998
by the Radiological Society of North America and the
Healthcare Information and Management Systems Society
(HIMSS) to define how existing standards should be used
to complete a particular healthcare task [85]. Similar to
HITSP specifications, IHE specifications could be devel-
oped to define how standards should be used to provide
CDS for personalized medicine.
Lessons Learned from Prior Efforts
Beyond these specific resources just described, the effort to
create a national CDS infrastructure for genomic and per-
sonalized medicine can leverage lessons learned from
within the U.S. and abroad. In this section, we review
some of these relevant insights.
First, with regard to how CDS needs to be delivered to cat-
alyze desired improvements in clinical care, we previously
identified 22 features of CDS interventions that had been
suggested to be important for CDS effectiveness by at least
three sources in the literature [29]. When evaluated
against the results of 70 randomized controlled trials of
electronic and non-electronic CDS interventions usingBMC Medical Informatics and Decision Making 2009, 9:17 http://www.biomedcentral.com/1472-6947/9/17
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multivariate regression analysis techniques, four of these
features were found to be significantly associated with a
CDS intervention's ability to lead to statistically and clin-
ically significant improvements in clinical care: automatic
provision of CDS as part of clinician workflow (p <
0.00001), provision of recommendations rather than just
assessments (p = 0.0187), provision of CDS at the time
and location of decision making (p = 0.0263), and the use
of a computer to generate the CDS (p = 0.0294) [29].
Moreover, through randomized controlled trials compar-
ing a CDS intervention against the same intervention aug-
mented by a specific feature, direct evidence is available
supporting the importance of providing CDS automati-
cally as a part of clinician workflow [86]; providing CDS
at the time and location of decision making [87]; supple-
menting point-of-care CDS with periodic user feedback
on compliance with the care standards recommended by
the CDS system [88]; and requiring clinicians to docu-
ment a reason when deviating from the recommendations
of a CDS system [89]. These insights from prior evalua-
tions of CDS interventions can inform how patient-spe-
cific care recommendations relating to personalized
medicine should be delivered to clinicians.
Moreover, when we analyzed existing approaches to the
integration of machine-processable knowledge resources
into clinical applications to enable CDS [31], we identi-
fied several general principles that are of relevance to
establishing a national CDS infrastructure. First, in order
to be widely useful, machine-processable medical knowl-
edge resources should be comprehensive in content cover-
age and as easy as possible to leverage within diverse types
of clinical information systems. Second, because
machine-processable medical knowledge is currently
encoded using a wide range of approaches, and because
efforts at adopting a universal approach to knowledge rep-
resentation have been unsuccessful to date despite a
number of attempts, support should be provided for
knowledge represented using different formalisms. Of
note, the use of a common service interface such as the
HL7 Decision Support Service interface [59] may allow
machine-processable medical knowledge represented
using different approaches to be leveraged in a consistent
manner. Finally, experience with the market's positive but
limited adoption of the HL7 Arden Syntax standard [42]
indicates that standardization can greatly facilitate the
market adoption of an approach to sharing CDS knowl-
edge but is insufficient on its own to drive widespread
adoption.
Finally, important insights are available from large-scale
health IT initiatives that have been ongoing at regional
and national levels. First, to establish a national health IT
infrastructure capable of supporting advanced CDS, sig-
nificant investments will be required. Launched in 2002,
England's effort to establish a national health IT infra-
structure, known as the National Programme for IT
(NPfIT), was estimated to cost £12.4 billion (approxi-
mately $19 billion) in a 2008 report by England's
National Audit Office [90]. In the U.S., an expert panel
has estimated that establishing a national health IT infra-
structure in the U.S. would cost $156 billion in capital
investments over five years, with annual operating costs of
$48 billion [91]. Second, large-scale health IT initiatives
involving multiple healthcare organizations are likely to
require significant government leadership and funding. In
the U.S., efforts at exchanging health information across
institutional boundaries have focused on the establish-
ment of regional health information exchange networks
known as regional health information organizations
(RHIOs). While successful and financially viable RHIOs
such as the Indiana Health Information Exchange [79] do
exist, of 145 RHIOs surveyed in 2007, only 20 were at
least of modest size and exchanging clinical data, and
eight of these RHIOs were heavily dependent on grant
funding to stay in operation [92]. These findings call into
question whether a national health IT infrastructure can
be established without significant and consistent funding
from the federal government [92]. Similar conclusions
can be drawn from a global survey of EHR implementa-
tion efforts published by HIMSS in August 2008 [93]. This
report evaluated EHR implementation efforts in Ger-
many, the Netherlands, Greece, England, Wales, Den-
mark, Norway, India, New Zealand, Malaysia, Hong
Kong, Singapore, Israel, Canada, and the United States
with regard to funding, governance, communication, and
standardization and interoperability. Based on the lessons
learned from these efforts around the globe, this report
concludes that developing a national, interoperable EHR
system in the U.S. will require the government to mandate
the use of appropriate standards; provide adequate fund-
ing; establish clearer governance structures and reduce
bureaucracy; and support improved communication
among the relevant stakeholders [93]. As CDS depends to
a large extent on the availability of a robust EHR infra-
structure, active leadership and substantial funding from
the federal government will likely be essential to the suc-
cessful implementation of a national CDS infrastructure
for genomic and personalized medicine.
Recommendations
To facilitate the widespread and consistent practice of
genomic and personalized medicine, we recommend that
the following actions be taken.
￿ First, we recommend that healthcare stakeholders
work together to develop a concrete action plan for
developing and implementing the five critical compo-
nents of a national CDS infrastructure as outlined in
Table 1. We provide in the next section an initialBMC Medical Informatics and Decision Making 2009, 9:17 http://www.biomedcentral.com/1472-6947/9/17
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action plan that could serve as the basis for developing
a more detailed plan moving forward.
￿ Second, we recommend that efforts at creating a CDS
infrastructure for genomic and personalized medicine
be integrated with an overall effort to support decision
making for all aspects of healthcare. Ultimately,
genomic medicine will need to be integrated seam-
lessly within existing clinical contexts and clinical care
pathways, such that genetically based medical inter-
ventions will be "just another aspect" of practicing
modern medicine. Accordingly, the CDS infrastructure
should fully support the use of both genomic and
non-genomic patient data to guide clinical care. This
integration of genomic medicine into clinical practice
will also require the addressing of other barriers to
clinical adoption, including the need for greater scien-
tific evidence validating the clinical value and cost
effectiveness of genetic and genomic assays [17-22], as
well as the need for educating healthcare professionals
regarding the appropriate use of genetics and genom-
ics in practice [17,19,22,23].
￿ Third, we recommend leveraging existing resources
to the greatest extent possible (Table 2).
￿ Fourth, we recommend that the national CDS infra-
structure be aligned with the strategic objectives set
forth in the Roadmap for National Action on CDS, which
was commissioned by ONCHIT and generated by an
expert AMIA task force in 2006 [28]. Of note, we have
previously described how a national CDS infrastruc-
ture can fulfill these strategic objectives through the
coordinated use of a number of the resources and
standards listed in Table 2, including centrally man-
aged knowledge repositories, Web-accessible software
services with standard HL7 interfaces, and standard
patient data models defined by HL7 and by other
standards development organizations [94].
￿ Fifth, we recommend that the federal government
lead the design, funding, and establishment of the
CDS infrastructure. As noted earlier, large-scale, cross-
organizational health IT efforts from the U.S. and
abroad indicate that government leadership and fund-
ing are critical to the success of such efforts [92,93].
Moreover, as noted by Dr. Don Detmer, the President
and Chief Executive Officer of AMIA, the federal gov-
ernment must lead the development of a national
health information infrastructure (NHII), because (i)
an NHII is a public good whose benefits accrue across
many stakeholders; (ii) the federal government has a
significant incentive to establish an NHII, as more
effective use of health IT could reduce the enormous
federal expenses associated with Medicare and Medic-
aid; and (iii) the private sector has insufficient central-
ized power or resources to lead such an effort [95].
￿ Sixth, given that less than 20% of U.S. clinicians cur-
rently utilize EHR systems in the ambulatory care set-
ting [96], we recommend that the CDS infrastructure
support both clinicians who already utilize EHR sys-
tems and clinicians who currently do not. To support
clinicians who do not utilize EHR systems, care recom-
mendations could potentially be provided using
administrative claims data and standardized labora-
tory data. For example, laboratories could potentially
utilize a patient's prior claims data to provide individ-
ually tailored interpretations of genetic and genomic
test results.
￿ Seventh, given increasing recent interest in personal
health records (PHRs) [97], including by major soft-
ware vendors such as Microsoft® [98] and Google®
[99], we recommend that the CDS infrastructure be
designed to also support personalized medicine
within the context of PHRs.
￿ Finally, when acquiring health information systems,
we recommend that clinicians and healthcare organi-
zations give preference to systems that provide robust
CDS capabilities using both genomic and non-
genomic patient data. We anticipate that such
advanced CDS capabilities will be most readily availa-
ble in information systems that take advantage of an
emerging national CDS infrastructure for genomic and
personalized medicine.
Proposed Framework for Action
We present here a proposed initial framework for moving
forward. We hope that this proposal will serve as the cata-
lyst for discussions and action that ultimately lead to the
establishment of a national CDS infrastructure for
genomic and personalized medicine.
As the first step, the U.S. federal CDS Collaboratory could
be clearly established as the organization that will lead the
effort to design, develop, and implement a national CDS
infrastructure supportive of personalized medicine.
Besides ONCHIT, AHRQ, and the Personalized Health
Care Initiative, federal agencies that could play central
roles in this process include the Department of Health
and Human Services, the National Institutes of Health,
the Food and Drug Administration, the CDC, the Veterans
Health Administration, the Military Health System, the
Health Resources and Services Administration, and the
Centers for Medicare & Medicaid Services (CMS). Cru-
cially, substantial funding will need to be secured by
members of the Collaboratory on an ongoing basis in
order for this effort to succeed. While led by federal agen-BMC Medical Informatics and Decision Making 2009, 9:17 http://www.biomedcentral.com/1472-6947/9/17
Page 11 of 14
(page number not for citation purposes)
cies, the Collaboratory should also work closely with non-
governmental organizations, including HITSP, CCHIT,
HL7, academic medical centers, healthcare delivery organ-
izations, and commercial health IT vendors.
Next, the Collaboratory could lead the definition of
desired CDS capabilities for personalized medicine in
terms of a large number of detailed use cases organized
under common patterns, and these use cases could be
used to define CCHIT EHR certification criteria. At the
same time, the Collaboratory could provide funding to
relevant domain experts in government, academia, and
industry to develop relevant standards within HL7 and to
specify how new and existing standards should be utilized
within the framework of HITSP. Moreover, CMS could
provide financial incentives for healthcare organizations
to obtain access to targeted CDS capabilities, similar to
how CMS currently provides a bonus to clinicians for
using electronic prescribing systems in their practices
[100].
Beyond leading the specification of the requirements of
clinical information systems supportive of personalized
medicine, the Collaboratory could internally develop
and/or fund the external development of HITSP-compli-
ant approaches to fulfilling the CCHIT certification crite-
ria in relation to personalized medicine. For example, the
NLM could lead an effort within the federal government
to develop freely accessible knowledge repositories for
personalized medicine in a manner similar to how it has
developed the UMLS terminology resource [65]. As
another potential approach, the federal government could
license knowledge resources from academic medical cent-
ers, professional medical associations, and/or commercial
entities so that these resources can be freely used by
healthcare organizations throughout the nation. This type
of arrangement already has a precedent in that the NLM
currently licenses SNOMED CT for approximately $6 mil-
lion per year so that anyone in the U.S. may use it free of
charge [101]. Moreover, these approaches to supporting
the adoption of CDS capabilities for personalized medi-
cine could be extended beyond the creation of knowledge
repositories. For example, the federal government could
provide internally developed or licensed software compo-
nents and support services to facilitate the creation of
secure health information exchange networks, so that
CDS systems can provide accurate advice even when
patients receive care across organizational boundaries.
Obviously, the extent to which these steps can be taken by
the federal government depends critically on the amount
of funding that can be secured for supporting health IT in
general and CDS specifically. While we recognize that
budgets are likely to remain tight within the federal gov-
ernment for some time, we are hopeful for progress given
President Obama's many public statements that health IT
is a key potential driver for more effective and cost-effec-
tive healthcare that is worthy of federal support [102].
Call to Seize the Limited Window of Opportunity
Given that genomic medicine is still in its early stages
[103], some may argue that it is premature to establish a
national CDS infrastructure for genomic and personalized
medicine. However, it is precisely because genomic medi-
cine is in its infancy that there is a significant opportunity
for directing the growth and development of a robust
infrastructure. Currently, only a limited amount of genetic
test data is stored in operational health information sys-
tems, and CDS for genomic medicine is still rare even in
research settings. If we do not establish a standards-based
infrastructure expeditiously, however, health information
systems will likely store increasing amounts of genomic
data using idiosyncratic approaches, and efforts at provid-
ing widespread, effective CDS for genomic medicine will
be severely hindered by the presence of entrenched infor-
mation systems that lack interoperability. To avoid this
modern-day Tower of Babel, we must act now while the
window of opportunity remains open.
Summary
Genomic medicine offers great promise for achieving a
more personalized and effective approach to disease pre-
vention, diagnosis, and therapy. To fulfill the full promise
of genomic and personalized medicine, however, a
national CDS infrastructure will be needed to guide the
appropriate use and interpretation of new genomic assays.
Core components of this required infrastructure include
centrally managed repositories of computer-processable
medical knowledge; standardization of the CDS informa-
tion to be provided for various aspects of genomic and
personalized medicine; standardized representation of
genomic and non-genomic patient data; standard
approaches for leveraging genomic knowledge repositor-
ies and patient data to guide clinical care; and a standard
approach for retrieving relevant patient data across health
information systems. In order to meet this important and
emerging need, we recommend the following: healthcare
stakeholders should come together to design and develop
the five components of the national CDS infrastructure
identified in this manuscript; efforts at creating a national
CDS infrastructure for genomic medicine should be inte-
grated with an overall effort to create a national CDS infra-
structure for all aspects of healthcare; existing resources
should be leveraged as much as possible; the national
CDS infrastructure should be aligned with the strategic
objectives of the U.S. Roadmap for National Action on CDS;
the federal government should lead the establishment of
the infrastructure; the infrastructure should support clini-
cians even if they do not have access to fully functional
EHR systems; the infrastructure should include supportBMC Medical Informatics and Decision Making 2009, 9:17 http://www.biomedcentral.com/1472-6947/9/17
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for PHRs; and when acquiring health information sys-
tems, healthcare organizations should select systems that
provide robust CDS capabilities using both genomic and
non-genomic patient data. Because genomic medicine is
still in its early stages of development, a limited window
of opportunity exists for establishing a robust, standards-
based, and interoperable CDS infrastructure before
healthcare organizations and health IT vendors develop
entrenched, institution-specific approaches to the prob-
lem that lack interoperability. We therefore call upon the
various healthcare stakeholders in the U.S. and elsewhere
to work expeditiously towards a national CDS infrastruc-
ture for genomic and personalized medicine, as the estab-
lishment of this infrastructure will be critical for enabling
a future in which each patient's unique genetic profile is
routinely considered to optimize health and healthcare.
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